Lehigh Valley Health Network

LVHN Scholarly Works
Research Scholars Poster Presentation

Creatinine Trends in Transcatheter Aortic Valve Replacement
Patients.
Sydney Pickering
Taryn Samet MD
James K. Wu MD
Lehigh Valley Health Network, james.wu@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/research-scholars-posters

Published In/Presented At
Pickering, S., Samet, T., Wu, J., (2017, July, 31) Creatinine Trends in Transcatheter Aortic Valve
Replacement Patients. Poster presented at: LVHN Research Scholar Program Poster Session, Lehigh
Valley Health Network, Allentown, PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion
in LVHN Scholarly Works by an authorized administrator. For more information, please contact
LibraryServices@lvhn.org.

Creatinine Trends in Transcatheter Aortic Valve Replacement Patients
Sydney Pickering, Taryn Samet, James Wu, MD
Department of Surgery, Division of Cardiothoracic Surgery

Lehigh Valley Health Network, Allentown, Pennsylvania

INTRODUCTION
• Omnipaque contrast dye is used for visualization
in patients undergoing transcatheter aortic valve
replacement (TAVR)
• Dye may impinge on the patient’s kidney health
• A previous study reported a wide range of 15%
to 57% of the TAVR patients developed acute
kidney injury after the TAVR procedure1

OBJECTIVE
• This study seeks to assess the creatinine
level of patients over time and analyze the
effects of the TAVR procedure on kidney
function

OUTCOMES

RESULTS
• Patients with pre-existing kidney issues:

356 TAVR
patients studied

262 with no
kidney issues

61 with preexisting kidney
issues

33 developed
kidney issues
post-procedure

12 with kidney
issues within 30
days of TAVR

21 with kidney
issues in more than
30 days post-TAVR

Figure 1: Flowchart Categorizing Kidney Issues in TAVR Patients

Reviewed

• This was a retrospective single-center observational study
• Included 356 patients with severe aortic stenosis who
underwent the TAVR procedure between January 2015June 2017 at the Lehigh Valley Health Network

• Electronic medical records were used to assess patient
creatinine levels before and after surgery and record the
amount of contrast dye used in the TAVR procedure

• Patients with no pre-existing kidney issues:
– there was no statistical significance showing that
patients who were given more dye were more likely
to develop a kidney disease post-TAVR
(p=0.3190).

• Patients who developed a kidney issue:
– there was no statistical significance showing the
patients who were given more dye were more likely
to develop a kidney disease within 30 days of the
TAVR procedure (p=0.8122).

CONCLUSIONS

METHODS

Classified

– there was no statistical significance showing the
patients who were given more dye had greater
changes in pre to post procedural creatinine levels
(p=0.5732).

Figure 2: Box Plot of Changes in Creatinine Levels Based on the
Concentration of Contrast Dye Administered
The box plots show the absolute value changes in creatinine levels
from the pre-TAVR workup to the 2 days post-TAVR labs.

• This was a negative study, revealing no statistical
significance that Ominpaque contrast dye
injections correlate to post-TAVR kidney issues
• Although there is always some risk that patients
develop chronic kidney disease or acute kidney
injury from the procedure, the results suggest that
the cardiac team should not deny patients as TAVR
candidates because of the possible complications
from using contrast dye
• Further research is recommended to assess the
effects of other contrast dyes on kidney function
and to extend the study to other tertiary hospitals.
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Analyzed

• Descriptive statistics were used to evaluate the
relationship between kidney function and the TAVR
procedure

